Roche has received CE marking from European regulators for its second Alzheimer's diagnostic test developed with Eli Lilly, clearing the way for marketing across the European Union. The test can confirm Alzheimer's disease and rule it out in neurology patients, a dual function Roche says will…
Roche has received CE marking from European regulators for its second Alzheimer's diagnostic test, developed in collaboration with Eli Lilly. The certification allows the test to be offered throughout the European Union and confirms that it meets the safety and performance standards required for the European market. It is the second test to come out of the Roche-Eli Lilly collaboration, which has produced one earlier Alzheimer's test, and the new certification expands the EU-approved diagnostic options available from the two companies.
The test is intended to support clinical decision-making in neurology settings. Roche describes it as able to confirm Alzheimer's disease, enabling clinicians to start appropriate treatment promptly, and able to rule Alzheimer's out when symptoms suggest other potential causes, redirecting the clinical workup toward alternative diagnoses. The dual confirmatory and exclusionary function is intended to improve diagnostic accuracy and make clinical workflows more efficient. The design reflects the reality of memory clinic referrals: many patients with cognitive symptoms do not have Alzheimer's pathology, and the diagnostic workup has to handle both groups.
Roche positions the CE marking as a key advancement in Alzheimer's detection and as an expansion of options for managing dementia. The framing responds to a demographic trend that is well documented across Europe: dementia prevalence is increasing among aging populations, and a reliable diagnostic test could support earlier intervention and better outcomes. Alzheimer's is the dominant cause of dementia and affects millions of people worldwide, a figure the announcement does not make more precise.
The collaboration behind the test combines biotechnology and pharmaceutical expertise, with Roche contributing the diagnostic platform and Eli Lilly contributing the pharmaceutical perspective. The partnership has now delivered two CE-marked Alzheimer's tests, an indication that both companies regard early and accurate detection as a necessary complement to their treatment work.
The CE mark attaches to the product itself, not to the companies or to the disease area. What Roche has obtained is the right to market this second test across the European Union, which means laboratories and hospitals in any member state can order it and run it. The earlier test from the partnership remains a separate product; the new certification does not modify the first one. The practical relationship between them, including whether the second test measures a different biomarker, uses a different sample type, or serves a different patient population than the first, has not been explained.
The intended use is worth parsing closely. This is a diagnostic aid for neurology, not a replacement for clinical judgment. A positive result is meant to confirm Alzheimer's in a patient being evaluated for cognitive impairment, clearing the way for treatment to begin. A negative result is meant to exclude Alzheimer's as the explanation for the symptoms, which is valuable in a different way: it prevents a misdiagnosis and sends the clinician toward other causes, from vascular dementia and frontotemporal degeneration to non-neurodegenerative conditions that can mimic dementia.
Confirmatory and exclusionary claims are two sides of the same measurement. Peptide biomarkers do not switch on and off; their concentrations change continuously, and the distinction between disease present and disease absent is made by a cut-off calibrated against a reference standard. By writing both interpretations into the intended use, Roche is signaling that the test is meant for the full spectrum of memory clinic referrals, not only for patients who already present with the classic Alzheimer's phenotype. That ambition raises the performance bar at both ends of the spectrum, and certification alone does not establish that the bar was met.
The treatment question sharpens the stakes. Newly available disease-modifying Alzheimer's therapies are indicated for patients with confirmed pathology, and a test that certifies the presence of disease can therefore act as a gatekeeper to treatment. A false negative would withhold treatment from a patient who could benefit; a false positive would expose a patient without Alzheimer's pathology to the risks of a therapy they do not need. Those two errors carry asymmetric consequences, and the clinical value of the test depends on which of them is more common, a question the announcement does not address.
CE marking is the European Union's conformity certification for regulated products, and for in vitro diagnostics it operates under the In Vitro Diagnostic Regulation EU 2017/746, which has applied since May 2022. The mark certifies that a device meets the safety and performance requirements set out in the regulation, and it functions as a passport: a CE-marked device may be marketed anywhere in the European Union without an additional national authorization for the device itself. The legal effect in this case is straightforward: the new Roche test may now be offered throughout the EU.
The governance structure differs from drug regulation. A medicine receives a marketing authorization from a central medicines agency or from national authorities, and the assessment documents are eventually published. A diagnostic device is certified through a different route. Under the IVDR, notified body involvement is required for all devices except the lowest-risk Class A products that have no measuring function and no sterile claim, so a clinical test of this kind necessarily passed through an independent conformity assessment. The notified body, an organization designated by a member state's competent authority, reviews the manufacturer's quality system and evaluates the evidence before the CE mark can be applied.
For a device intended to diagnose a disease with serious health consequences, the evidence package under the regulation typically covers three layers. Scientific validity concerns the link between the measured analyte and the clinical condition. Analytical performance concerns whether the assay measures that analyte accurately and reproducibly. Clinical performance concerns whether the result distinguishes diseased from non-diseased patients in the intended population. The notified body reviews that evidence, and the manufacturer remains responsible for post-market surveillance, including the investigation of incidents that occur once the device is in routine use. The assessment documentation itself is not published, which is why the clinical evidence behind a CE mark is generally invisible to researchers and clinicians.
The regulation's risk tiers scale the depth of that assessment. In vitro diagnostics are classified from Class A, the lowest risk, to Class D, the highest, and scrutiny increases with the class. The class of this test was not disclosed, but a clinical assay intended to support diagnosis is at least Class B under the regulation, and every class above A requires notified body assessment. The practical consequence is that a CE mark of this kind is not a manufacturer's self-declaration. It represents an independent review of both the quality system that produced the device and the evidence that supports its intended use.
What the mark does not do is just as important. It does not set a price, guarantee reimbursement by any national health service, or place the test in clinical guidelines; those decisions are made separately by each member state, usually through health technology assessment. It also does not certify that the test outperforms an existing method such as amyloid PET or cerebrospinal fluid analysis. It certifies that the device met the regulatory standards in effect at the time of assessment. That is a meaningful hurdle, but it is a different claim from clinical superiority.
Alzheimer's disease is defined by the accumulation of two misfolded protein species in the brain. Amyloid-beta peptides, most notably the 42-residue form known as Aβ42, aggregate into extracellular plaques, while hyperphosphorylated tau protein assembles into intracellular tangles that track more closely with cognitive decline. Both are peptide-based species, which is why the Alzheimer's diagnostics field is, at bottom, a peptide measurement field. Amyloid-beta and tau assays detect these peptides directly, and the regulatory milestone announced by Roche lands squarely in that domain.
The biology that such a test exploits is measurable from the earliest stages of the disease. Aβ42 is produced when β-secretase and γ-secretase cleave the amyloid precursor protein. In the cerebrospinal fluid of a person with amyloid pathology, the concentration of soluble Aβ42 falls because the peptide is being sequestered into plaques, and the ratio of Aβ42 to the more abundant 40-residue Aβ40 drops correspondingly. Phosphorylated tau species, particularly those carrying phosphorylations at threonine 181 or threonine 217, rise in the fluid compartment as tau pathology develops. Modern assays detect one or more of these analytes, in cerebrospinal fluid obtained by lumbar puncture or increasingly in blood plasma, and the clinical performance of any given test depends on which analyte is chosen and how the cut-off is set.
The confirm and exclude logic follows from that biology. Under the biological definition of Alzheimer's disease that now anchors clinical research, formulated by the National Institute on Aging and the Alzheimer's Association, amyloid pathology is the initiating event and tau pathology tracks with symptoms. A patient with cognitive symptoms and a positive amyloid signal falls on the Alzheimer's continuum; a patient with a negative amyloid signal does not have the disease's defining pathology, and the clinician is directed to other explanations for the symptoms. That is the conceptual foundation for a test with both confirmatory and exclusionary intended uses.
The cut-off problem sits in the middle of this logic. Peptide concentrations change continuously across the presymptomatic, prodromal, and dementia phases, and no concentration declares a diagnosis by itself. The test designer chooses a threshold, calibrates it against a reference standard such as amyloid positron emission tomography or neuropathological examination, and accepts the trade-off between sensitivity and specificity that the threshold produces. A threshold set to maximize detection will classify more healthy people as diseased; a threshold set to minimize false positives will miss more early cases. Which direction this manufacturer chose has not been disclosed.
The specimen matrix adds another layer of analytical difficulty. Cerebrospinal fluid is the more established matrix: it sits adjacent to the brain, the peptide concentrations are relatively high, and a generation of clinical studies has defined expected values. But lumbar puncture is invasive and poorly tolerated by many elderly patients, which limits how quickly a test can be deployed in memory clinics. Plasma assays are far easier to scale, yet the concentrations of amyloid-beta and tau peptides in blood are orders of magnitude lower, the matrix is more complex, and the assays must contend with interference from abundant plasma proteins and with the peripheral metabolism of the peptides themselves.
All of this bears on what the Roche announcement does and does not say. The biology described here is the field the test enters; the announcement does not state which peptide the test measures, whether it uses cerebrospinal fluid or blood, whether it is a single-analyte assay or a ratio, or how the cut-off was established. What can be said with…
Related reading: FDA Takes Aim at GLP-1 Compounders in Pharmacies, FDA Proposes Excluding GLP-1s from 503B Bulk List, FDA Moves to Restrict Bulk Compounding of Novo, Lilly Weight-Loss Drugs, Daily Orforglipron Preserves Weight Loss After Semaglutide or Tirzepatide.